Athenex Inc
$
14
0.16 (1.16%)
| Volume: | 337,876 | Avg Vol (1m): | 382,444 |
| Market Cap $: | 1.08 Bil | Enterprise Value $: | 1.04 Bil |
| P/E (TTM): | 0.00 | P/B: | 8.76 |
| Earnings Power Value | 0 |
| Net Current Asset Value | 0.56 |
| Tangible Book | 0.88 |
| Projected FCF | 0 |
| Median P/S Value | 16.12 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 5/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1.50 |
Cash-To-Debt ranked
higher than
50.09%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ATNX:
1.5
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 1.27, Med: 11.97, Max: 64.03
Current: 1.5
|
| Equity-to-Asset | 0.49 |
Equity-to-Asset ranked
higher than
65.01%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ATNX:
0.49
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.32, Med: 0.65, Max: 0.79
Current: 0.49
|
| Debt-to-Equity | 0.45 |
Debt-to-Equity ranked
higher than
92.20%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ATNX:
0.45
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.06, Max: 0.98
Current: 0.45
|
| Debt-to-EBITDA | -0.32 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ATNX:
-0.32
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -0.39, Med: -0.23, Max: -0.02
Current: -0.32
|
| Piotroski F-Score | 2 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 0.68 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -1.43 |
Not Manipulator
Manipulator
| |
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -200.08 |
Operating Margin ranked
lower than
50.25%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ATNX:
-200.08
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -417.24, Med: -326.38, Max: -142.33
Current: -200.08
|
| Net Margin % | -189.86 |
Net Margin ranked
lower than
52.40%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ATNX:
-189.86
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -426.82, Med: -353.84, Max: -131.81
Current: -189.86
|
| ROE % | -105.59 |
ROE ranked
lower than
71.79%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ATNX:
-105.59
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -211.83, Med: -117.97, Max: -51.87
Current: -105.59
|
| ROA % | -67.89 |
ROA ranked
lower than
72.05%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ATNX:
-67.89
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -106.51, Med: -70.37, Max: -42.02
Current: -67.89
|
| ROC (Joel Greenblatt) % | -878.29 |
ROC (Joel Greenblatt) ranked
lower than
58.98%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ATNX:
-878.29
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -1622.13, Med: -1116.27, Max: -750.87
Current: -878.29
|
| 3-Year Total Revenue Growth Rate | 85.60 |
3-Year Revenue Growth Rate ranked
lower than
100.00%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ATNX:
66.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
| N/A |
| 3-Year Total EBITDA Growth Rate | -35.40 |
3-Year EBITDA Growth Rate ranked
lower than
100.00%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ATNX:
-21.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
| N/A |
» ATNX's 30-Y Financials
Financials (Next Earnings Date: 2019-08-14)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:ATNX
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | NAS:MRTX SZSE:000518 SHSE:603896 NAS:RGNX HKSE:01681 SAU:2070 SZSE:300149 NAS:GERN NYSE:BHVN SZSE:002872 SZSE:300255 NAS:AMRN XPAR:GNFT XKRX:102940 SZSE:300204 NAS:NTLA XKRX:078160 HKSE:06826 SZSE:002022 SZSE:300147 |
| Traded in other countries | 2MT.Germany |
| Address | 1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203 |
| Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 8.76 |
PB Ratio ranked
lower than
71.93%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ATNX:
8.76
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 4.93, Med: 7.56, Max: 11.21
Current: 8.76
|
| PS Ratio | 12.08 |
PS Ratio ranked
lower than
55.51%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ATNX:
12.08
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 7.88, Med: 13.94, Max: 44.92
Current: 12.08
|
| EV-to-EBIT | -6.86 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ATNX:
-6.86
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -11.8, Med: -6.65, Max: -3.9
Current: -6.86
|
| EV-to-EBITDA | -7.01 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ATNX:
-7.01
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -12.3, Med: -6.8, Max: -4
Current: -7.01
|
| EV-to-Revenue | 13.63 |
EV-to-Revenue ranked
lower than
51.75%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ATNX:
13.63
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 7.4, Med: 13.2, Max: 37.5
Current: 13.63
|
| Current Ratio | 2.22 |
Current Ratio ranked
lower than
56.24%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ATNX:
2.22
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.17, Med: 3.12, Max: 4.46
Current: 2.22
|
| Quick Ratio | 1.85 |
Quick Ratio ranked
lower than
58.29%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ATNX:
1.85
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.98, Med: 2.73, Max: 3.86
Current: 1.85
|
| Days Inventory | 157.06 |
Days Inventory ranked
lower than
53.22%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ATNX:
157.06
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 69.38, Med: 120.74, Max: 176.07
Current: 157.06
|
| Days Sales Outstanding | 98.08 |
Days Sales Outstanding ranked
higher than
71.11%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ATNX:
98.08
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 49.32, Med: 67.15, Max: 100.31
Current: 98.08
|
| Days Payable | 133.89 |
Days Payable ranked
higher than
75.19%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ATNX:
133.89
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 100.92, Med: 153.41, Max: 242.04
Current: 133.89
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -11.60 |
3-Year Share Buyback Rate ranked
lower than
100.00%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ATNX:
-11.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
| N/A |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 15.91 |
Price-to-Tangible-Book ranked
lower than
76.06%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ATNX:
15.91
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 8.82, Med: 13.21, Max: 21.2
Current: 15.91
|
| Price-to-Median-PS-Value | 0.87 |
Price-to-Median-PS-Value ranked
higher than
68.88%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ATNX:
0.87
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.65, Med: 1.02, Max: 2.74
Current: 0.87
|
| Earnings Yield (Joel Greenblatt) % | -14.62 |
Earnings Yield (Greenblatt) ranked
lower than
52.27%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ATNX:
-14.62
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -25.8, Med: -15.05, Max: -8.4
Current: -14.62
|
More Statistics
| Revenue (TTM) (Mil) $ | 76.57 |
| EPS (TTM) $ | -2.22 |
| Beta | 0 |
| Volatility % | 42.2 |
| 52-Week Range $ | 9.38 - 20.9 |
| Shares Outstanding (Mil) | 77.07 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 2 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |